Tempus ECG-AF vs ClearRead CT

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Tempus ECG-AF

by Tempus AI, Inc.

ClearRead CT

by RIVERAIN TECHNOLOGIES

AI Verdict

Tempus ECG-AF is designed for early identification of atrial fibrillation risk using 12-lead ECGs, primarily for geriatric patients. In contrast, ClearRead CT enhances the detection and characterization of pulmonary nodules and assesses coronary artery calcification from CT scans. While both leverage AI in cardiovascular health, they address different diagnostic challenges with distinct input modalities.

Choose Tempus ECG-AF if…

Choose Tempus ECG-AF if your primary goal is to proactively identify elderly patients (65+) at increased risk of developing new-onset atrial fibrillation within the next year. This tool is ideal for integrating into routine geriatric or internal medicine screenings, leveraging existing 12-lead ECG data to support earlier intervention and follow-up for AF risk management.

View Tempus ECG-AF →

Choose ClearRead CT if…

Choose ClearRead CT if you need to enhance the accuracy and efficiency of interpreting cardiothoracic CT scans for pulmonary nodules and coronary artery calcification. This AI suite is best suited for radiology departments seeking to improve nodule detection, characterization, and tracking, as well as streamline CAC scoring, ultimately reducing reading times and improving diagnostic confidence.

View ClearRead CT →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Tempus ECG-AF	ClearRead CT
Pricing	Contact vendor	Contact for pricing
Deployment	Software solution, integrated into healthcare facility systems with advanced cardiology algorithms.	On-premise (stand-alone server, virtual machine) and Cloud
BAA Available	Yes AI-estimated	Unknown
FDA Status	Yes AI-estimated	Cleared AI-estimated
HIPAA	Yes AI-estimated	Unknown

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

ClearRead CT

ClearRead CT emphasizes seamless PACS integration and vendor-neutral processing, which are critical for smooth integration into existing radiology workflows. Studies also indicate a significant reduction in reading times (up to 36%), directly enhancing the user experience for radiologists.

Clinical Value

ClearRead CT

While both tools offer significant clinical value, ClearRead CT provides a more direct and quantifiable impact on diagnostic accuracy for critical conditions. It demonstrates a 29% reduction in missed actionable nodules and high agreement with ground truth radiologists for coronary artery calcification scoring.

Pricing & Value

Tempus ECG-AF

Tempus ECG-AF offers greater pricing transparency by explicitly stating CMS reimbursement CPT codes (0764T and 0765T) and a specific Medicare rate of $128.90, effective January 1, 2025. This provides a clear financial pathway for healthcare providers.

Enterprise Readiness

ClearRead CT

ClearRead CT demonstrates stronger enterprise readiness through its flexible deployment options (on-premise and cloud), vendor-neutral PACS integration, and ISO27001 certification. It also boasts compatibility and validation with all major AI platforms and CT manufacturers, ensuring broad adaptability.

Innovation

Tempus ECG-AF

Tempus ECG-AF's predictive capability to identify patients at increased risk of developing atrial fibrillation within 12 months from a standard ECG represents a groundbreaking application of AI. This shifts the paradigm from reactive diagnosis to proactive risk stratification, earning it the first FDA clearance in its category.

Support & Docs

ClearRead CT

ClearRead CT offers more comprehensive and transparent support resources, including dedicated customer care contact information with specified hours, online FAQs, manuals, system requirements, and workflow guides. The availability of 'Customer Success Live Sessions' (webinars) further enhances user education and support.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Tempus ECG-AF	ClearRead CT
Primary Function	Analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months.	Enhances pulmonary nodule detection and coronary artery calcification analysis in CT scans, improving diagnostic accuracy, reducing reading times, and streamlining radiology workflows.
Analyzed Data Type	12-lead ECG recordings	CT scans
Target Condition/Risk	New onset Atrial Fibrillation (AF) within 12 months for patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery.	Pulmonary nodules (solid, part-solid, ground glass), Coronary Artery Calcification (CAC) scoring.
Supported Specialties	Cardiology, Geriatrics, Internal Medicine	Cardiology, Pulmonology, Radiology
Key AI Capabilities	AI-based algorithm for 12-lead ECG analysis, detects signs associated with new onset Atrial Fibrillation (AF) within 12 months.	Pulmonary Nodule Detection, Patented Vessel Suppression, Nodule Characterization and Measurement, Automated Nodule Tracking and Comparison, Coronary Artery Calcification (CAC) Scoring.
Reimbursement Information	CMS reimbursement available (CPT 0764T and CPT 0765T to APC 5734, Medicare rate of $128.90, effective January 1, 2025).	Contact vendor for details

Videos

Demos, reviews, and walkthroughs featuring Tempus ECG-AF and ClearRead CT.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What are the primary clinical applications of each AI tool?

Tempus ECG-AF is an AI-based algorithm that analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months, supporting earlier identification and follow-up. ClearRead CT is an AI suite that enhances pulmonary nodule detection and coronary artery calcification analysis in CT scans, aiming to improve diagnostic accuracy, reduce reading times, and streamline radiology workflows.

What type of diagnostic data does each tool analyze?

Tempus ECG-AF specifically analyzes 12-lead ECG recordings. ClearRead CT analyzes CT scans, including both contrast and non-contrast chest CTs.

Which patient populations are these tools intended for?

Tempus ECG-AF is intended for patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery. ClearRead CT is indicated for use in adults aged 18 years and older who are asymptomatic, and it is not cleared for pediatric use.

Is there established reimbursement for using these AI tools?

Yes, Tempus ECG-AF has CMS reimbursement available with CPT codes 0764T and 0765T, assigned to APC 5734, with a Medicare rate of $128.90, effective January 1, 2025. For ClearRead CT, Medicare code G0680, effective April 1, 2026, allows for reimbursement of AI-powered detection and quantification of coronary artery calcium and aortic valve calcification from routine chest CT scans, with rates determined by regional Medicare Administrative Contractors.

What key features and functionalities do these tools provide to physicians?

Tempus ECG-AF offers an AI-based algorithm for 12-lead ECG analysis to detect signs associated with new onset AF within 12 months. ClearRead CT provides features such as pulmonary nodule detection (solid, part-solid, ground glass), patented vessel suppression for an unimpaired view of the chest, nodule characterization, measurement, automated tracking and comparison to prior exams, and coronary artery calcification (CAC) scoring on ungated, non-contrast CTs.